For human embryonic stem cells (hESCs) to be used clinically, it is imperative that immune responses evoked by hESCs and their derivates after transplantation should be prevented. Human leukocyte antigens (HLA) and ABO blood group antigens are important histocompatibility factors in graft rejection. HLA matching between recipient and unrelated donors, in particular, is important in improving outcomes in hematopoietic cell transplantation (HCT). We have established and successfully maintained 29 hESC lines and analyzed the HLA and ABO genotypes of these lines. HLA-A, -B, -C and -DR (DRB1) genotyping was performed by polymerase chain reaction (PCR) sequence-based typing and ABO genotyping was carried out by PCR restriction fragment length polymorphism methods. To determine what proportion of the Korean population would be covered by these cell lines in organ transplantation, 27 cell lines with HLA-A, -B, and -DR data were evaluated for HCT (cord blood) donors and 28 cell lines with HLA-DR and ABO data were evaluated for solid organ (kidney) transplantation donors, and then compared the data with those from 6,740 donated cord bloods. When 2 HLA mismatches are allowed for HCT, as currently accepted for cord blood transplantation, it was estimated that about 16% and 25% of the possible recipients can find one or more donor cell lines with ≤2 mismatches at A, B, DRB1 allele level and at A, B antigen/DRB1 allele level, respectively. When HLA-DR antigen level matching and ABO compatibility was considered for solid organ (kidney) transplantation, it was estimated that about 29% and 96% of the possible recipients can find one or more ABO-compatible donor cell lines with 0 and 1 DR mismatches, respectively. We provided the first report on the HLA and ABO genotypes of hESC lines, and estimated the degree of HLA and ABO matching in organ transplantation for the Korean population.
INTRODUCTION
strated that the resulting cells are homogeneous and do not form teratomas or cause cancer (40) . Third, the immune response/rejection caused by transplantation of The development of human embryonic stem cells (hESCs), with their unlimited proliferation and differen-hESCs or their differentiated derivatives should be prevented. tiation ability, raises hope in patients that scientists may one day be able to cure currently untreatable illnesses.
The culture conditions for the derivation and maintenance of hESCs necessary for clinical applications, such Reaching that goal will require overcoming certain problems with hESCs. First, the derivation, maintenance, and as cell therapy, have been established very rapidly, especially given the relatively recent development of the differentiation of hESCs should be accomplished under xeno-free culture condition using good manufacturing field. The first report of hESC derivation in 1998 (65) described an immunosurgery procedure for the isolation practice (GMP) systems (32, 58, 66) . Second, guided differentiation methods of hESCs into a given functional of inner cell mass (ICM) cells, the use of mouse embryonic fibroblast (MEF) cells as feeder cells, and fetal bo-cell type must be established, and it must be demon-vine serum (FBS)/leukemia inhibitory factor (LIF) as MHC class II genes are HLA-DP, -DQ, and -DR. The proteins (antigens) encoded by HLA are expressed components of the culture medium. Currently, basic fibroblast growth factor (bFGF) is the most important fac-uniquely on the surface of cells in the body, and are used to distinguish self from non-self; thus, differences tor for maintaining pluripotency, and Knockout serum replacement (SR) and various human feeder cells origi-in MHC proteins become a serious impediment for transplantation of hESCs or their differentiated deriva-nating from fetal skin, fallopian tube, foreskin, uterine endometrium, and other tissues have replaced FBS and tives. In fact, a number of reports have suggested that the risks of severe graft-versus-host disease (GvHD), MEFs in hESC culture (1, 2, 17, 27, 29, 43, 54) . To avoid contamination of animal-derived components during the graft failure, and mortality increase in proportion to HLA disparity in allogeneic hematopoietic cell trans-derivation procedure, mechanical isolation of ICM has been introduced instead of immunosurgery (60) . Re-plantation (HCT) using bone marrow or umbilical cord blood (7, 31, 49, 50, 57) . It is very difficult to find suitable, searchers have attempted to develop defined culture media to allow culture of hESCs without feeder cells or SR fully HLA-matched donors; nevertheless, it is important to minimize HLA mismatching between donor and pa- (3, 17, 35, 37, 67, 68, (70) (71) (72) . The generation of clinicalgrade hESC lines under GMP conditions was recently tient to maximize graft outcome. Another factor to be considered for transplantation is ABO blood group anti-reported, although these cells were prepared using US FDA-approved clinical-grade materials instead of a gens. ABO compatibility between the donor and recipient has long been considered an absolute requirement xeno-free method (10).
It has been expected that stem cells and their deri-for successful solid organ transplantation, although ABO incompatibility is not an obstacle for successful HCT (9). vates could be used for cell therapy as they might replace damaged tissue or organ (44) . Unlike other stem
The ideal solution for avoiding or minimizing immune response/rejection in allogeneic transplantation is cells, hESCs have demonstrated true pluripotency, with the potential to differentiate into all three germ layer to use donor cells that are genetically identical to those of the patient. One way to accomplish this is by deriva-lineage cells (4, 20, 45, 52) . Thus, differentiated cells from hESCs could be used to replace virtually any damaged tion of hESCs from oocytes generated by somatic cell nuclear transfer (SCNT); another is to reprogram a pa-tissue or organ. To accomplish their therapeutic goals, transplanted cells must not be rejected by the patient's tient's somatic cells, creating induced pluripotent stem cells (iPS) (25) . There are currently no reports demon-immune system (56) . Previous reports have shown that undifferentiated hESCs expressed low levels of major strating successful establishment of hESCs through SCNT, perhaps because of potential ethical concerns as-histocompatibility complex (MHC) class I proteins but do not express MHC class II proteins (14, 34) . Moreover, sociated with this method. Since Takahashi and Yamanaka (63) first reported the induction of pluripotent stem it was reported that, during differentiation in vitro and in vivo, the expression levels of MHC class I proteins cells from somatic cells in mice, there have been several reports describing the successful production of iPS in in hESCs increased but MHC class II proteins were not expressed on differentiated hESCs (14). The presence mice and humans using defined factors (22, 38, 41, (46) (47) (48) 69) . At present, the procedure for reprogramming to of MHC antigens on hESCs might induce an immune response; thus, hESCs injected in vivo across histocom-generate iPS cells mostly involves genetic modification using viral transduction, making it difficult to apply the patibility barriers would be at risk for rejection (6) . Studies have reported that hESCs or their derivatives iPS solution in a clinical context, although some researcher have shown that iPS are able to be generated have low immunostimulatory potential and failed to stimulate proliferation of alloreactive human T cell (34) , without virus construction (23, 59, 73) . The next option is to establish a hESC bank that has a large number of and have shown that undifferentiated hESCs formed teratomas in immunocompetent mice after humanization hESC lines, which collectively match HLA and ABO types in a majority of patients. In the last 10 years, more by injection of human peripheral blood leukocytes (13). In contrast, it was reported that hESCs transplanted into than 400 hESC lines have been established and studied worldwide (International stem cell registry, University immunocompetent mice were effectively recognized and rejected by the adaptive murine immune system (62) . of Massachusetts medical school; http://www.umass med.edu/iscr/index.aspx) (16, 18) ; therefore, the organi-The immunogenicity of hESCs and their differentiated derivatives, especially in vivo, is still not well under-zation of a large bank of hESC is not impossible. In 2005, using HLA data from 10,000 cardiac organ donors stood.
A number of genes for human leukocyte antigens and 6,577 patients awaiting kidney transplants in the UK, Taylor et al. (64) estimated that approximately 150 (HLA) are highly polymorphic and encode various MHC class I and II proteins; the three major MHC class hESC lines would be needed to establish a therapeutic hESC bank capable of providing an HLA match for I genes are HLA-A, -B, and -C, and the three major most potential patients. Nakajima et al. (42) also esti-MO) in DMEM/F12 or acid Tyrode's solution (Sigma) in DMEM/F12. The trophoectoderm (TE) was then re-mated that a bank containing 170 hESC lines could offer at least one hESC line with a single mismatch at one moved by immunosurgery using an anti-human whole serum antibody (Sigma H-8765) and guinea pig comple-HLA loci to 80% of patients in the Japanese population. If parthenogenetic homozygous hESC lines could be es-ment (Sigma S-1639 or Calbiochem 234395, La Jolla, CA), or by mechanical isolation through manual transfer tablished, the number of hESC lines needed to establish such a bank would be reduced from 170 to as few as 55 of ICM outgrowths after seeding intact blastocysts on feeder cells. The STO cell line (ATCC CRL-1503, Man-under the same conditions.
To date, we have established 31 hESC lines under assas, VA) or mouse embryonic fibroblasts (mEFs) were used as mouse feeder cells; human embryonic fibro-various conditions that comply with the derivation of clinical-grade hESCs, and have successfully maintained blasts (hEFs) or human foreskin fibroblasts (hFSs) were used as human feeder cells after mitotic inactivation by 29 such lines in the CHA Stem Cell Institute, Korea. We have analyzed the HLA-A, -B, -C, and -DR geno-mitomycin C (Sigma) treatment. hEFs and hFSs were established from aborted human fetuses and human fore-types of these 29 hESC lines (CHA-hES 3-26, M1, and R1-R4) by polymerase chain reaction (PCR) sequence-skin tissue after obtaining informed consent. After spreading the ICM clump on feeder cells, ES cell-like based typing, and performed ABO genotyping using PCR restriction fragment length polymorphism method.
colony was cultured and mechanically dissected into small clumps every 5-6 days. ES cell colonies were cul-We successfully determined the ABO genotypes of all hESC lines and obtained HLA-A, -B, -C, and -DR geno-tured in DMEM/F12 medium supplemented with 20% Knockout SR, 0.1 mM β-mercaptoethanol, 1% nones-type results from 27 of the 29 lines; the exceptions were two hESC lines that showed chromosomal triploidy/tet-sential amino acids, 100 U/ml penicillin, 100 µg/ml streptomycin, and 4 ng/ml basic fibroblast growth factor raploidy, and HLA-A, -C, and -DR results were obtained in one of these two cell lines. In this study, we compared (bFGF; all products from Gibco/Invitrogen, Grand Island, NY) at 37°C in a humidified 5% CO 2 incubator. the HLA and ABO genotypes of the CHA-hESC lines as donors with those of 6,740 donated cord blood sam-hESCs were cyropreserved by transferring hESC clumps stepwise into media containing incremental in-ples as recipients to determine what proportion of the Korean population would be covered by these cell lines creases in SR and DMSO (final composition: 90% SR + 10% DMSO), loaded into 0.25 ml straws (IMV, L'Aigle for cell/tissue transplantation. For a simulation of matching these cell lines as possible organ donors, 27 cell cedex, France; 30-70 clumps/straw), and frozen using a programmed cell freezer (CryoMagic, Mirae Biotech, lines with HLA-A, -B, and -DR data were evaluated for HCT (cord blood) and 28 cell lines with HLA-DR and Korea) (30) . To confirm endogenous alkaline phosphatase activity ABO data were evaluated for solid organ (kidney) transplantation. Our results demonstrate that established and hESC-specific surface marker expression in established hESCs, we stained hESC colonies with an FRV-hESC lines have a potential as HCT donors with ≤2 ABDR (A, B antigen/DRB1 allele level) mismatches alkaline, sodium nitrite, and naphthol AS-BI alkaline solution mixture (Sigma) for 20 min at room temperature and as ABO-compatible solid organ (kidney) donors with 0 DR (antigen level) mismatch for 25% and 29% (RT), and performed immunocytochemistry using antibodies against SSEA-4 and TRA 1-60 (Chemicon, Tem-of the Korean population, respectively. ecula, CA) after fixing with 4% paraformaldehyde MATERIALS AND METHODS (PFA). We also ascertained the Oct-4 gene expression hESC Derivation, Maintenance, and Characterization status by reverse transcription-polymerase chain reaction (RT-PCR) or immunocytochemistry using an anti-OCT-Frozen human embryos from pronucleus to blastocyst stage were donated by couples undergoing infertility 4 antibody (Chemicon). The following primer sequences were used for Oct-4: (forward) 5′-gga aag gct tcc ccc tca treatment after obtaining informed consent and approval by the Institutional Review Board (IRB) of CHA Gang-ggg aaa gg-3′, (reverse) 5′-aag aac atg tgt aag ctg cgg ccc-3′ (460 bp). A fluorescein-labeled goat anti-mouse nam Medical Center. All processes followed IRB guidelines prior to 2005 and then relevant laws enacted since IgG antibody (Molecular Probes, Eugene, OR) was used as a secondary antibody and nuclei were stained with 2005. After thawing, donated embryos were cultured in sequential media to the blastocyst stage for 1-6 days:
DAPI (Vector Laboratories, Burlingame, CA).
For the cytogenetic analysis of hESCs, they were in-P1/Blastocyst medium (Irvine Scientific Inc. Santa Ana, CA) or G1.2/G2.2 medium (Vitrolife, Englewood, CO). cubated for 3 h in hESC culture medium containing 0.1 µg/ml colcemid (KaryoMax colcemid solution; Gibco-hESC lines were established by removing the zona pellucida of blastocysts (except hatched blastocysts) by BRL). Thereafter, they were treated with a hypotonic solution (1% sodium citrate buffer) for 30 min and then treatment with 0.3% pronase (Sigma P-5147, St. Louis, fixed with methanol and acetic acid (3:1, v/v). Cells remaining CHA-hESC lines were established on mouse feeder cells. Twenty-nine CHA-hESC lines have been were spread onto a glass slide and dried, and chromosomes were identified by G banding. For karyotyping of cryopreserved at various passages; all 24 hESC lines that have been thawed were found to be viable, and an each cell lines, more than 20 metaphase chromosomes were counted by an expert. additional 5 hESC lines that have not yet been thawed are available for the future use (Table 1) . Each hESC line was characterized with respect to short tandem repeat (STR) loci by DNA fingerprinting.
All hESC lines showed endogenous alkaline phosphatase activity and were positive for SSEA-4, TRA 1-Genomic DNA was extracted and 15 STR loci (D3S1358, TH01 The differentiation capacity of each hESC line was loidy/tetraploidy)-had abnormal karyotypes (Table 1) . DNA fingerprinting results ( Table 2 ) were in agreement confirmed by injecting undifferentiated hESCs into a testicle of an NOD/SCID male mouse as clumps (about with the gender and triploidy results of karyotypic analyses, and demonstrated that each of the 29 hESC lines 1 × 10 6 cells/150 µl PBS). After 14-20 weeks, teratomas were excised, fixed in PFA, embedded in paraffin, sec-were distinct from one other. The differentiation potential of the 26 karyotypically normal hESC lines was de-tioned, and then analyzed histologically after staining.
termined by injecting hESCs into the testicle of an HLA and ABO Genotyping NOD/SCID male mouse. Twenty-three hESC lines, such as CHA-hES 3-15, 17, 18, 22, 23, 24, M1, and R1-R4, Donated cord blood data, which included HLA genotypes and ABO blood group antigens, was provided by formed teratomas, and their teratomas showed that these hESCs differentiated into various cell types composed iCORD (Cord Blood Bank of CHA Bio & Diostech Co., Seoul, Korea) and compared with HLA and ABO geno-of three germ layers (http://csci.cha.ac.kr/CHA-hES Clines). Teratoma formation by injection of CHA-hES types determined for CHA-hESC lines.
High resolution (allele level) HLA typing of hESC 20, 21, and 25 is currently under examination to confirm their differentiation ability using various stains. The and cord blood was performed by PCR sequence-based typing using a Secore Sequencing Kit (Invitrogen, karyotypically abnormal hESC lines such as CHA-hES 16, 19, and 26 have not been tested for teratoma forma-WI), using a DNA Engine Tetrad Thermal Cycler (Bio-Rad, Hercules, CA) and an Applied Biosystems 3130xl tion. Previous reports showing that classical HLA typing Genetic Analyzer (Applied Biosystems, Foster City, CA). HLA-A, -B, -C, and -DR genotypes were deter-by serological methods (serotyping) is inaccurate have led to the development of the more precise gene se-mined for hESC, and HLA-A, -B, and -DR genotypes were determined for donated cord blood.
quencing method (genotyping). In this study, we performed high-resolution HLA-A, -B, -C, and -DR typing ABO genotyping was performed by PCR restriction fragment length polymorphism using the restriction en-of our 29 hESC lines and obtained complete HLA typing results from all but two ( tion, 2 digits) were homozygous for HLA-A; two (low-level (high-resolution, 4 digits) as well as at A, B antigen/DRB1 allele level. The assignment of serological resolution) were homozygous for HLA-C; and one (high-resolution) was homozygous for HLA-DRB1.
antigens for particular HLA alleles were carried out on the basis of The HLA Dictionary 2008 (21) . Table 4 To determine what proportion of the Korean population would be matched for these hESC lines in terms of shows that among 6,740 cord blood samples as possible recipients of HCT, 14 (0.21%), 117 (1.74%), and 958 organ transplantation, we compared HLA and ABO types of the hESC lines as donors with those of 6,740 (14.21%) could find 0, 1, and 2 mismatches, respectively, at A, B, and DRB1 allele level. When we consid-donated cord blood samples as recipients. The donated cord blood data were provided by iCORD, one of the ered A, B antigen/DRB1 allele level of matching, these figures were increased to 20 (0.30%), 164 (2.43%), and Korean private cord blood banks. For a simulation of HCT (cord blood), 27 cell lines with HLA-A, -B, and 1,510 (22.4%), respectively. Thus, a total of 1,089 (16.16%) and 1,694 (25.13%) possible recipients could -DR data were evaluated and for a simulation of solid organ (kidney) transplantation, 28 cell lines with HLA-find one or more donor cell lines with ≤2 mismatches at A, B, DRB1 allele level and at A, B antigen/DRB1 al-DR and ABO data were evaluated as possible donors. For HCT, we compared HLA data at A, B, DRB1 allele lele level, respectively. 10/13 9/11 11/11 9/10 8/12 D7S820 11/11 11/11 12/12 9/12 11/12 9/11 10/10 9/12 8/11 9/11 11/12 11/12 11/12 10/12 9/10 D16S539 11/14 9/11 11/13 9/10 9/13 9/13 9/11 9/9 9/12 9/10 9/9 11/12 11/11 9/11/12 10/11 CSF1PO 12/12 10/11 10/13 12/12 10/11 12/12 12/12 10/11 9/12 11/11 12/12 12/12 12/12 10/12 11/11 Penta D 8/9 10/13 9/9 11/11 9/9 9/13 9/10 12/13 11/12 11/11 8/13 9/9 9/11 8/9/12 10/ 10/13 11/12 12/13 9/12 11/13 11/12 11/11 9/12 10/11 10/11 9/11 11/12 9/13 9/13 10/11/12 D13S317 8/12 9/11 8/11 8/12 9/12 8/11 11/12 11/11 8/11 12/13 11/12 9/9 8/12 8/9 8/9/10 D7S820 10/11 10/12 11/12 11/12 10/10 11/12 8/11 8/12 11/12 10/11 11/11 12/12 10/11 8/10 10/11/13 D16S539 9/10 10/12 9/9 9/11 9/10 10/10 10/13 11/11 9/13 9/10 9/13 10/12 9/11 9/12 9/11/12 CSF1PO 9/10 10/12 11/12 9/10 12/12 12/13 11/11 10/10 9/12 12/12 11/11 11/13 10/11 10/12 11/12 Penta D 9/12 9/14 12/12 9/9 11/13 9/10 8/9 9/11 8/10 9/9 9/13 9/13 11/11 8 A second type of histocompatibility antigens, the ered, a total of 3,013 (44.7%) and 6,668 (98.93%) possible recipients could find 0 and 1 DR antigen mismatched do-ABO blood group antigens, is also important to be considered in matching donor and recipient, especially in nor cell lines, respectively. When ABO compatibility was also considered, these figures were decreased to 1,957 solid organ transplantation. Matching of ABO blood type is not essential in HCT, although ABO incompati-(29.04%) and 6,456 (95.79%), respectively. bility may cause hemolysis after transplantation (61) .
DISCUSSION Table 3 shows the results of our examination of the ABO blood types of 29 CHA-hESC lines. Ten of these Since the first report of hESC establishment, more than 400 hESC lines have been established worldwide CHA-hESC lines were type A (A/A or A/O), nine were type B (B/B or B/O), eight were type O, and two were (International stem cell registry, University of Massachusetts medical school; http://www.umassmed.edu/ type AB. In consideration of solid organ (kidney) transplantation (http://www.unos.org), we analyzed HLA-DR iscr/index.aspx) (16, 18) . There is also an effort on the part of several stem cell registries to disseminate infor-(DRB1) antigen level matching and ABO compatibility (O to A, B, O, and AB; A to A and AB; B to B and mation regarding various hESC lines; the emergence of large banks of hESC lines would be a logical next step AB; AB to AB) between 28 CHA-hESC lines as possible donors and 6740 donated cord blood samples as possible that may not be long in coming. Based on HLA matching using data from donors and patients for organ/cell recipients ( Table 5 ). When only HLA match was consid- transplantation, the number of hESC lines needed for a with HLA-DR and ABO data as possible donors and 6,740 donated cord bloods as possible recipients for therapeutic hESC bank has been estimated at approximately 150 in the UK and 200 in Japan (42, 64) . How-solid organ (kidney) transplantation revealed that about 29% and 96% of the possible recipients could find ABO ever, no reports have calculated the number of hESC lines needed for a bank using the HLA type of hESC compatible donor cell lines with 0 and 1 HLA-DR antigen mismatches, respectively. lines. In this study, we performed high-resolution HLA genotyping of HLA-A, -B, -C, and -DR, obtaining com-Realizing this potential and applying hESC-based cell therapy clinically requires that a number of techni-plete results from 27 of the 29 CHA-hESC lines typed. An evaluation of the 27 cell lines with HLA-A, -B, and cal issues be surmounted. First, the derivation of clinical-grade hESC lines must not involve exposure to ani--DR data as possible donors and 6,740 donated cord bloods as possible recipients for HCT (cord blood) mal materials during the derivation/propagation process so as to avoid the risk of infection or an immune reac-showed that about 16% and 25% of the possible recipients could find one or more donor cell lines with ≤2 tion to animal substances. Also, all processes from embryo production to hESC establishment and differentia-mismatches at A, B, DRB1 allele level and at A, B antigen/DRB1 allele level, respectively. We also analyzed tion should be performed according to a GMP system in consideration of clinical use (33, 58, 66) . As the hESC the ABO genotypes of all 29 CHA-hESC lines and found that 34.5% (10/29) were type A, 31.0% (9/29) derivation method and culture condition have been developed into xeno-free system, we have successfully es-were type B, 21.6% (8/29) were type O, and 6.9% (2/ 29) were type AB. An evaluation of the 28 cell lines tablished and maintained 29 hESC lines in GMP-grade culture room under various conditions (Tables 1 and 2) . hESCs that complies with regulations governing the use of human cells and cellular-based products intended for The modifications made to achieve these near-clinicalgrade hESCs include changing the hESC derivation/ tissue repair and replacement in the US. If these hESC lines prove suitable for therapeutic use, the first step to-propagation method from immunosurgery to mechanical isolation of ICMs, and switching from mouse feeder ward clinical application of hESCs would be largely solved. cells to human feeder cells. We have also recently begun using human serum instead of FBS for feeder cell cul-A second important aspect of hESC technology that must be resolved is the immunogenicity of hESCs, an ture, but have not yet had an opportunity to apply this modification to the establishment of new hESC lines.
issue that has not been well studied. At the core of the immune system are the MHC genes, which encode pro-Xeno-free SR from Invitrogen has recently come into the market as a next-generation substitute for SR, but its teins expressed on the surface of cells; in humans, the genetic subset that encodes cell surface antigens are the ability to support growth and maintain the characteristics of hESCs has not yet been verified. Crook et al. (10) HLA genes. MHC class I molecules are found on most cells of the body, where they present peptides from cyto-reported the generation of six clinical-grade hESC lines using current GMP-compliant materials and procedures.
solic proteins that are recognized by cytotoxic T cells. MHC class II molecules are found only on a few cell Although the authors of this study did not use material that originated from humans, they developed a model types, including macrophages, dendritic cells, and B cells, and present peptides from exogenous proteins that for applying GMP to the production of clinical-grade 26) , it is still worth considering. Our shown that undifferentiated hESCs weakly express MHC class I antigens on the cell surface, but do not results indicate that the possibility of finding 0 HLA-DR mismatches between our 28 CHA-hESC lines as possi-express MHC class II (14, 34) . When hESCs differentiate into embryoid bodies (EBs) in vitro, their expression of ble donors and 6.740 donated cord bloods as possible recipients for solid organ transplantation decreased from MHC class I is increased, but MHC class II proteins remain undetected (14). Treatment of undifferentiated 45% to 29% when ABO compatibility was taken into account. hESCs with interferon-γ has also been shown to induce the expression of MHC class I proteins, which are also Studies of HLA matching in unrelated donor HCT using high-resolution matching have shown that match-increased in EBs by treatment with interferon-α, -β, or -gamma (14). Drukker et al. (13) reported that hESCs ing all five HLA loci [HLA-A, -B, -C (class I) and -DRB1, -DQB1 (Class II)] lowers the risks of clinically or their differentiated derivatives transplanted into human peripheral blood mononuclear cell-reconstituted severe GvHD, graft failure, and mortality, and further showed that these risks are amplified with increasing mice were not rejected and developed normally into teratomas. Cabrera et al. (8) suggested that the low expres-degree of locus mismatch (49). Although a perfect match is clearly ideal, in reality it is very difficult to sion of MHC class I on hESCs was caused by downregulation of antigen-processing machinery (APM) find HLA full-matching unrelated donors. The current standard for the selection of cord blood units includes components, similar to mechanisms in tumor cells, as shown by the low or absent expression of APM compo-HLA-A, -B, and -DR typing, and the vast majority of cord blood transplantations have been performed using nents in the HS293 hESC line. Based on these data, it has been suggested that hESCs and their derivatives units with match grades of 6/6, 5/6, or 4/6 at HLA-A, B antigen level, and HLA-DR allele level (15,24,28,55). A have an immune-privileged status. A recent report has reached an opposite conclusion, however, reporting that similar situation exists with respect to using hESCs and their derivates for donor cell source for HCT: while it hESCs transplanted into immunocompetent mice were effectively recognized and rejected by the adaptive mu-would be desirable to find HLA full-matching hESCs for each patient, in practice it would require quite a large rine immune system (62) . Using molecular imaging techniques, this article showed that hESC survival after number of hESC lines. If two HLA-type mismatches are assumed to be acceptable for transplantation of hESCs, transplantation was significantly limited in immunocompetent mice compared to immunodeficient mice, and re-as is the case for cord blood transplantation programs, it was estimated that our 27 CHA-hESC lines can cover peated transplantation of hESCs into immunocompetent mice resulted in accelerated hESC death.
about 16% and 25% of the Korean population with A, B, DR allele level and A, B antigen/DR allele level If the immune character of hESCs is capable of eliciting an immune response upon transplantation, the im-matches, respectively. None of our 27 CHA-hESC lines was homozygous at all of the HLA-A, -B, and -DR loci, mune reaction caused by transplanted hESCs must be solved before clinical application of hESCs. The strate-and very few were homozygous at an individual locus. Ultimately, establishing hESC lines with homozygous gies for preventing hESC immune recognition are (i) establishment of large banks of immunophenotyped hESC HLA genotypes would be very helpful as this would reduce the number of hESC lines needed for a therapeutic lines to match MHC alleles between hESC lines and patients; (ii) generation of isogenic hES cell lines by so-hESC bank. In this context, hESC lines established from human parthenogenetic blastocysts have been shown to matic cell nuclear transfer using the patient's own somatic cells or parthenogenesis of oocytes; (iii) induction possess homozygous HLA genotypes (36, 53) . Although this latter strategy raises practical problems that would of tolerance by hematopoietic chimerism using hematopoietic cells differentiated from hESCs; (iv) creation of need to be resolved, this approach might prove to be a practical way to create a full complement of HLA geno-universal cells by genetic modification to reduce the expression of MHC molecules; (v) transplantation of types using a minimal number of hESC lines. When we analyzed HLA-DR antigen level matching hESCs into immune-privileged sites, including the eye, brain, or testis; and (vi) use of immunosuppressive med-and ABO compatibility between 28 CHA-hESC lines as possible donors and 6,740 donated cord bloods as possi-ications (5, 11, 12, 51) .
Matching ABO blood group antigens is another fac-ble recipients for solid organ (kidney) transplantation (Table 5) , it was estimated that 28 CHA-hEC lines can tor that contributes to the success of transplantation (61) . Recently, Mölne et al. (39) reported that hESCs and dif-cover almost one third (29%) of the Korean population with 0 DR mismatch and vast majority (96%) of the ferentiated hepatocyte-and cardiomyocyte-like derivatives expressed ABO blood group antigens. Although population with 1 DR mismatch. In summary, we provide the first report on the HLA ABO matching may seem less important than HLA type matching in hematopoietic stem cell transplantation, in and ABO blood group genotypes of 28 CHA-hESC bryonic stem cell line HS293 is associated with the APM lines, and estimated the degree of HLA and ABO match- comes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia:
